Related references
Note: Only part of the references are listed.Human papillomavirus vaccination in adults: impact, opportunities and challenges – a meeting report
Dur-e-Nayab Waheed et al.
BMC Proceedings (2021)
Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation
Arnaud John Kombe Kombe et al.
FRONTIERS IN PUBLIC HEALTH (2021)
CX-4945 and siRNA-Mediated Knockdown of CK2 Improves Cisplatin Response in HPV(+) and HPV(-) HNSCC Cell Lines
Janeen H. Trembley et al.
BIOMEDICINES (2021)
An Overview of Novel Agents for Cervical Cancer Treatment by Inducing Apoptosis: Emerging Drugs Ongoing Clinical Trials and Preclinical Studies
Lei Liu et al.
FRONTIERS IN MEDICINE (2021)
Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300
Mauro Rosales et al.
BIOMEDICINES (2021)
Protein kinase CK2: a potential therapeutic target for diverse human diseases
Christian Borgo et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial
Leticia R. Cruz et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2021)
Host proteome linked to HPV E7-mediated specific gene hypermethylation in cancer pathways
Nopphamon Na Rangsee et al.
INFECTIOUS AGENTS AND CANCER (2020)
Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis
Marc Arbyn et al.
LANCET GLOBAL HEALTH (2020)
CIGB-300 anticancer peptide regulates the protein kinase CK2-dependent phosphoproteome
Yasser Perera et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2020)
Clinical-Grade Peptide-Based Inhibition of CK2 Blocks Viability and Proliferation of T-ALL Cells and Counteracts IL-7 Stimulation and Stromal Support
Yasser Perera et al.
CANCERS (2020)
The HPV-18 E7 CKII phospho acceptor site is required for maintaining the transformed phenotype of cervical tumour-derived cells
Om Basukala et al.
PLOS PATHOGENS (2019)
Activity of CK2α protein kinase is required for efficient replication of some HPV types
Alla Piirsoo et al.
PLOS PATHOGENS (2019)
CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation
Silvio E. Perea et al.
SEMINARS IN ONCOLOGY (2018)
Mapping the interactome of HPV E6 and E7 oncoproteins with the ubiquitin-proteasome system
Juline Poirson et al.
FEBS JOURNAL (2017)
The PTPN14 Tumor Suppressor Is a Degradation Target of Human Papillomavirus E7
Anita Szalmas et al.
JOURNAL OF VIROLOGY (2017)
Integration of Human Papillomavirus Genomes in Head and Neck Cancer: Is It Time to Consider a Paradigm Shift?
Iain M. Morgan et al.
VIRUSES-BASEL (2017)
Cancer-type dependent expression of CK2 transcripts
Melissa M. J. Chua et al.
PLOS ONE (2017)
Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer
M. R. Sarduy et al.
BRITISH JOURNAL OF CANCER (2015)
Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia
Nagayasu Egawa et al.
VIRUSES-BASEL (2015)
Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models
Yasser Perera et al.
MOLECULAR AND CLINICAL ONCOLOGY (2014)
Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization
Yasser Perera et al.
JOURNAL OF PEPTIDE SCIENCE (2012)
Phosphorylation events during viral infections provide potential therapeutic targets
Julie A. Keating et al.
REVIEWS IN MEDICAL VIROLOGY (2012)
The Biology and Life-Cycle of Human Papillomaviruses
John Doorbar et al.
VACCINE (2012)
Safety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies
Ana M. Solares et al.
BMC CANCER (2009)
Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity
Yasser Pereira et al.
MOLECULAR CANCER THERAPEUTICS (2009)
CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo
Silvio E. Perea et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2008)
Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor
KyungWon Huh et al.
JOURNAL OF VIROLOGY (2007)
Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A
D Pim et al.
ONCOGENE (2005)
Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2)
SE Perea et al.
CANCER RESEARCH (2004)
Interaction of the HPV E7 proteins with the pCAF acetyltransferase
N Avvakumov et al.
ONCOGENE (2003)
Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7
SL Gonzalez et al.
JOURNAL OF VIROLOGY (2001)
Differential phosphorylation of the HPV-16 E7 oncoprotein during the cell cycle
P Massimi et al.
VIROLOGY (2000)
Share Paper
